Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.

Slides:



Advertisements
Similar presentations
Indicators for monitoring ARV treatment outcomes.
Advertisements

Contribution of Economics to Operational Research for Evaluation of Scaling Up Access to HIV Care & Treatment in Developing Countries Presentation by Pr.
Priority Issues and Strategic Information Needs for Kenya in scaling up ART.
TB/HIV Integration What it entails Frank Lule, Eyerusalem Negussie, Reuben Granich, Haileyesus Getahun.
NIMH R34 MH82654 “A Multimedia Social Support Intervention: Adherence to HIV Care In South Africa”
Overview of the Global Fund: Guiding Principles Grant Cycle / Processes & Role of Public Private Partnerships Johannesburg, South Africa Tatjana Peterson,
ART: The Basics William Aldis World Health Organization Bangkok, September 14, 2005.
Presentation to the 2014 International AIDS Conference
Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department July 20th, 2014 Evidence.
Experience under the TAP: Determinants and experience with adherence in Burkina Faso Hospital and Community Sites in Burkina Faso Pascal NIAMBA, Cecile.
Treatment challenges of 2 nd /3 rd line HIV/AIDS, hepatitis-C in Seychelles BY DR LOUINE MOREL.
Scaling up Prevention of Mother to Child Transmission of HIV (PMTCT): What Will it Take to Eliminate MTCT? Jessica Rodrigues Presentation for UNICEF Written.
Service Integration in the Context of PEPFAR Programming David Hoos September 2010.
Fast-track to ending AIDS in Zimbabwe: opportunities
Kevin Fenton, MD, PhD, FFPH Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers for Disease Control and Prevention.
HIV in Suriname Ministry of Health Suriname M.Sigrid Mac Donald – Ottevanger, MD Focal point HIV Treatment and Care, NAP.
TITLE from VIEW and SLIDE MASTER | 27 July 2006 AID EFFECTIVENESS FOR HEALTH: TOWARDS THE 4TH HIGH-LEVEL FORUM, BUSAN AID EFFECTIVENESS FOR HEALTH.
SAfAIDS,ZAN LEARNING AND SHARING EVENT Feedback from the XVII International AIDS Conference 2008 Emerging Issues in Workplace Programmes.
PMTCT at Different Levels of Care: The Uganda Experience Dr. Saul Onyango National PMTCT Coordinator Ministry of Health 1 1.
Ilesh V. Jani, MD PhD Instituto Nacional de Saúde Maputo, Mozambique.
Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.
Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.
Overview Burkina--- ART Population: 11 millions Prevalence: 6.6% (surveillance data) Estimate of 650,000 PLWHA 300 peoples with red cross 2000 people to.
HIV Treatment and Care Research priorities Facilitator – Dr Saphonn Vonthanak 12 participants 29 agreed topics –not grouped on methodology or subject category.
Group Discussion Guyana, The Bahamas T & T, Jamaica Barbados, Haiti Suriname, Curacao.
JNB/05 HIV/AIDS treatment - challenges in a remote rural area of Tanzania. Johan N. Bruun Department of Infectious Diseases Ullevål University Hospital.
1 HIV/AIDS Related Research Agenda Workshop Phnom Penh, Sunway Hotel March 28-29, 2007.
Joan Holloway Vice President, Global Health Initiatives Multidisciplinary Care Team Delivery of Integrated HIV Services.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
The PHRplus Project is funded by U.S. Agency for International Development and implemented by: Abt Associates Inc. and partners, Development Associates,
6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,
1 Global Health Research How the private sector contribute Bergen, 22. September 2004 Birger Sørensen, President CEO Bionor Immuno AS.
The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department.
Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July
Task Shifting in Malawi around delivery of antiretroviral therapy Anthony D Harries “The Union” Paris, France.
Evaluating HIV Prevention and Treatment Programs Damien de Walque Markus Goldstein.
Pioneering IMAI: Developing an integrated approach in Uganda Dr Elizabeth Madraa, Program Manager National STD/AIDS Control Program MOH - UGANDA 5 th Dec.
Monitoring UA 2010 in health sector 1 |1 | Monitoring progress towards Universal Access 2010 in the health sector Kevin M De Cock Ties Boerma.
ICAP Track 1.0 Year 6: Reaching Targets Focus on Quality Continued Innovations David Hoos, MD, MPH Dar es Salaam August 4, 2009.
Psychosocial support model for community - based ART initiatives: Zimbabwe experience. Sostain Moyo G.Kadzirange, L. S. Zijenah, T. Kufa. L. Gwanzura,
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
WHO PMTCT ARV Guidelines 2012 Programmatic Update EFV During Pregnancy Nathan Shaffer PMTCT Technical Lead, WHO IATT Webinar 11 July, 2012.
Christo van Niekerk, M.D. Senior Director, Clinical Development Pretoria, South Africa Innovating TB Treatment: Opportunities for Private Sector Engagement.
Providing Treatment, Restoring Hope Program Updates Dr. Robb Sheneberger, MD University of Maryland School of Medicine Track 1.0 Implementers Meeting Dar.
Promoting Rational Use of ARVs in HIV/AIDS Clinics in Tanzania Presented by Salama Mwakisu -MSH.
Securing the Supply of Condoms and Other Essential Products for HIV/AIDS Programs Tony Hudgins Yasmin Chandani John Snow Research & Training Institute.
Philippe Chiliade, MD, MHA Technical Advisor, Clinical Care, FHI 12 August 2008 Family Health International Implementing HIV Care & Treatment Progress.
Prevention of Mother to Child Transmission Antiretroviral Drugs to Prevent MTCT.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
From HIV Testing to Treatment: Operations Research to Improve ARV Treatment Programs Treatment Acceleration Program Meeting November 30, 2006 Mark Micek,
Facility supervision by the District Health Teams (DHTs) in Rwanda Track1 Meeting Maputo, Mozambique, August 10 th -12 th Dr. Ruben Sahabo.
Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.
World Vision Experiences in Making ART Treatment Affordable and Available Dr. Daniel J Malleboyina M.B.B.S, MBA, MPH Regional Advisor HIV & AIDS- Asia.
Implementing operational research for HIV treatment scale-up in resource-limited settings TB/HIV Research Priorities in Resource-Limited Settings Expert.
ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.
11 Laboratory Quality Improvement for clinical HIV/AIDS Services in the Uniformed Forces Mwaibako, J, Shija, L; Haverkamp, G; van den Hombergh; Katebalila,
Public-Private Partnership to Scale Up and Sustain TB and HIV Care in Ethiopia Tesfai Gabre-Kidan, MD Country Director, Private Health Sector Abt Associates.
How differentiated care supports “Tx all” and Dr
EVALUATION OF ANTIRETROVIRAL THERAPY FOLLOWED BY AN EDUCATIONAL INTERVENTION TO INCREASE APPROPRIATE USE IN ZIMBABWE.
Health system assessments
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
Introduction to poster session and discussion
South Africa: From ProTest to Nationwide Implementation
From ProTEST to Nationwide Implementation
Essentials Policy Protocols Training Technical Mentorship
Fabio Scano IUATLD Conference Paris, 2003
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing Referred to HIV clinic for: HIV counseling Treatment of OIs CTX proph. HAART If HIV+ Continue at TB clinic for: TB treatment New system TB patient treated at TB center “Opt-out” HIV testing at TB center Rotating VCT counselors TB nurses Referred to HIV clinic for: HIV counseling Treatment of OIs HAART If HIV+ Continue at TB clinic for: HIV counseling TB treatment CTX proph.

How to improve referral? Better counseling? Streamline treatment of TB patients at HIV clinic? Decentralize more HIV services to TB sites? CD4 counts HAART

Summary Current ART’s effective but further innovation of dose, safety and efficacy desirable Drug development costs in HIV rising Developing world concentration of epidemic presents unique challenges –Clinical Trial Conduct –Regulatory –Distribution and Access –Pharmacovigilance Learning from PPP’s to address challenges

HAART in pregnancy... Is effective and the results are independent from the setting of delivery Makes possible the breastfeading Present a very limited life-threatening risk and the hepatic toxicity seems, in a large cohort, to be limited

HAART in pregnancy... Is well accepted by the patients: 80% of the invited women completed the protocol Is associated with a decreased rate of viral resistance compared with single dose nevirapine Is cost-effective

Concluding remarks Adherence and preventive behaviours are inadequate No clear association between individual factors and adherence Decreasing adherence over time: –second year of treatment “high risk” for non- adherence Implications for antiretroviral resistance Need for prospective studies of adherence to treatment AND prevention

Public Health Approach to Treatment Utilize 1 st line regimens with predictable mutations and “dead end mutational pattern” Utilize 1 st line regimens which allow for rational 2 nd line therapies Be willing to change 1 st line therapeutic approach based on resistance data despite costs Invest more heavily on community treatment support/adherence programs to ensure high level initial adherence

Conclusion  Some of the ART program related risks are real, we need to do much more in moving on the options to mitigate against them  Many of the ART program related benefits are real and substantial, we need to do much more on the options to optimize them

Next steps Study impacts on adherence and treatment outcomes of: –Impact of out-of-pocket expenses and transportation costs (w. household data) –Type of facility and service quality –Other variables … Similar work in Ghana, Mozambique, Rwanda, South Africa and Kenya

Ingredients of a successful AIDS Transition A “Learning Agenda” will help accomplish the AIDS transition Understand the health & non health benefits of treatment in each country Understand all the determinants of treatment success in each country Financing problem: Lower costs, increase effectiveness or increase funding? Prevention, prevention, prevention

CONCLUSION TAP has contributed at the national level to the greater involvement of PLWHI elegible for ARV treatment. TAP has increase an honest collaboration between public health facilities and NGOs. There is a need to be cautious while implementing resistance sentinel sites of HIV/AIDS and ART. ART is a essential in Burkina Faso and needs to be continued.

Conclusion FHI under TAP has engaged the private sector to demonstrate its complementary role to the public sector in ART roll out in Ghana The pro-poor approach of TAP brings in an element of equity since it can target both the rich and the poor TAP has demonstrated that quality standards of HIV care and treatment can be assured by the private sector through constant engagement Q: AFTER TAP WHAT NEXT?

Key Lessons  Desire for quick results led to more centralized & vertical approaches at outset; shift towards integration essential at this stage of program  Important potential impact of AIDS investments in terms of work environment (staff recruitment and training, laboratory upgrading, facility rehabilitation, and logistical support)  Good ownership & empowerment with performance based financing approach; enhanced accountability and performance  Importance of impact evaluation (i.e. measuring performance contracting; impact of treatment on prevention)